No Data
Shanghai MicuRx Pharmaceutical (SHSE:688373) Has Debt But No Earnings; Should You Worry?
MicuRx Pharma Launches New Packaging for Contezolizumab Tablets; Shares Drop 3%
MediGene Pharmaceuticals (688373.SH): New packaging specifications for contizolam tablets are now on sale.
On December 12, Gelonghui reported that Mengke Pharmaceutical (688373.SH) announced the recent launch of a new packaging specification for a box of 12 tablets of Triazolam, which will soon begin sales. This new packaging specification product will explore the agency sales model, aiming to leverage external resources and the advantages of agents in market reach to quickly expand into more regional markets. Triazolam tablets are a new type of antibiotic developed by the company with global intellectual property rights. Triazolam tablets (specification: 400mg) were approved by the National Medical Products Administration (NMPA) of China on June 1, 2021, for the treatment of complicated skin infections.
Express News | Shanghai Micurx Pharmaceutical Co Ltd - Trial Achieved Primary Efficacy Endpoint, Nda Process to Follow
Shanghai MicuRx Pharmaceutical Completes Third Phase Trial of MRX-4 Tablets
Express News | Shanghai Micurx Pharmaceutical Co Ltd - Mrx-5 Generally Well Tolerated in Phase 1 Study
